A Single-arm, Open-label, Phase III Trial to Evaluate the Safety and Tolerability of Intra-articular Injections of RTX-GRT7039 in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee.
A Single-arm, Open-label, Phase III Trial to Evaluate the Safety and Tolerability of Intra-articular Injections of RTX-GRT7039 in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee.
An open-label, single-arm clinical trial to confirm the safety of monoarticular injections or bi-lateral intra-articular injections of RTX-GRT7039 in patients who have pain associated with osteoarthritis of the knee despite standard of care.
This trial comprises a total observation period of up to 78 weeks.
Inclusion Criteria:
Exclusion Criteria:
The non-index knee is not eligible for treatment in the trial, if any of the knee-related exclusion criteria applies to the non-index knee.
Veliko Tarnovo, 5000, Bulgaria
Okawa-shi, Fukuoka 831-0016, Japan
Shinjuku-ku, Tokyo 169-0073, Japan
Wroclaw, Lower Silesian Voivodeship 50-556, Poland
Poznan, 60-218, Poland